Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | 80 mg AZD8529 |
|
| 2 | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AZD8529 | Drug | 2 capsules by mouth for 3 days |
| |
| Placebo to match AZD8529 |
| Measure | Description | Time Frame |
|---|---|---|
| Functional magnetic resonance imaging (fMRI) | 1 fMRI on Day 4; 1 fMRI on Day 21 | |
| Computerized neurocognitive tests | 1 on Day -1; 1 on Day 1 and on Day 21 |
| Measure | Description | Time Frame |
|---|---|---|
| Positive and Negative Syndrome Scale (PANSS) | Day-1; Day 4; Day 17; Day 21 | |
| Electroencephalography (EEG) | Day 4; Day 21 | |
| Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Raquel Gur | Hospital of the University of Pennsylvania, Dept of Psychiatry, Neuropsychiatry Section | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Philadelphia | Pennsylvania | United States |
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000608263 | AZD8529 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
2 capsules by mouth for 3 days |
|
| Labs at screening and on Days -1, 4, 17, 21, and 35; ECG at screening and Day 35; Physical Exam at screening and Day 35; Vital signs at screening and Days -1,4, 17, 21, and 35 |
| Suicidality assessment, collection of adverse events | Suicidality assesment at screening; and Days -1, 4, 17, 21, and 35 Adverse events at screening, and Days -1,4,17,21, and 35 |